Competency information

Details

Measure the radiochemical purity of a prepared radiopharmaceutical such as technetium-99m-labelled methylene    diphosphonate   (MDP) using a miniaturised two-system thin-layer chromatography (TLC) assay

  • Calculate percentage purity and see if it meets the required specification
  • Repeat the assay towards the end of the shelf life of the material
  • Complete the documentation to record these activities

Considerations

  • Radiopharmaceuticals in routine clinical practice together with any particular problems arising from their use.
  • Activities normally undertaken in a hospital radiopharmacy.
  • Radiopharmaceuticals preparation.
  • Quality assurance in radiopharmacy in particular and describe the most important means of control of aseptic preparation and how the principles of quality assurance are routinely applied in a radiopharmaceutical production system.
  • Nomenclature, principles, and mechanisms of atomic reactions.
  • The design and principles of particle accelerators and nuclear reactors and their relevance for production of radionuclides used in nuclear medicine.
  • Qualitative and quantitative terms the interactions of radiation with biological systems.
  • Relative risks of nuclear medicine procedures compared with other potentially hazardous life events.
  • The principles of the most important types of radiation detectors used in nuclear medicine together with the way in which they are normally employed.
  • The structure of the atom, the most important means of radioactive decay of unstable nuclei and the types of radiation emitted there from.
  • Radionuclides used in nuclear medicine:
    • the relationships between their physical properties, their  clinical applications, and their strengths and weaknesses
    • the radiopharmaceutical chemistry of these radionuclides
    • the influence of these chemical properties on the biodistribution of their radiopharmaceuticals
    • the different formulations used in nuclear medicine; properties and preparation
    • radiopharmaceutical kits and reagents used therein.
  • Technetium-99m generators.
  • Methods of measuring molybdenum breakthrough and radiochemical purity.

Relevant learning outcomes

# Outcome
# 7 Outcome Measure the radiochemical purity of a prepared radiopharmaceutical such as technetium-99m labelled methylene diphosphonate (MDP) using a miniaturised two-system thin-layer chromatography (TLC) assay.
# 6 Outcome Complete the documentation that would normally be used to record these activities in the radiopharmacy.